WASHINGTON — Researchers are making strides toward understanding and detecting Alzheimer’s disease in its earliest stages, when interventions may be most effective at slowing the progress of the disease. The findings will be presented on Sunday, November 12, 11:30 a.m. – 12:30 p.m. EST at Neuroscience 2023 , the annual meeting of the Society for Neuroscience and the world’s largest source of emerging news about brain science and health.
Alzheimer’s disease (AD) is a neurodegenerative disorder predicted to affect 8.5 million people by 2030. Individuals with AD may experience mild cognitive impairment and the accumulation of abnormal proteins in their brains for years before the onset of dementia. Early detection is important for effective intervention, but existing diagnostic methods can be subjective, expensive, or invasive. Understanding the biological and cognitive changes associated with early AD is necessary for early detection, monitoring, and treatment of this disease.
New findings show that:
“Early detection of Alzheimer’s disease is key for the efficacy of current interventions as well as for evaluating the effectiveness of new therapies,” says Virginia Lee, Director of the Center for Neurodegenerative Disease Research at the University of Pennsylvania. “The research advances presented today may lead to future diagnostics to help in prognosis, measure disease progression, and evaluate therapies.”
This research was supported by national funding agencies including the National Institutes of Health and private funding organizations. Find out more about social behavior and the brain on BrainFacts.org.
Sunday, November 12, 2023
11:30 a.m. – 12:30 p.m. EST
Walter E. Washington Convention Center, Room 202B
Alzheimer’s Disease Press Conference Summary
Comprehensive profiling of plasma proteome in mild cognitive impairments identifies high-performance blood biomarkers for early screening and classification of Alzheimer’s disease
Yuanbing “Jason” Jiang, yuanbing@ust.hk , Abstract PSTR198.18
Sex-based trajectory differences in longitudinal biomarker, cognitive, and structural measures after onset of amyloid-β accumulation
Keenan Walker, keenan.walker@nih.gov , Abstract PSTR198.19
Development of a high-performance blood-based biomarker panel for the early screening and classification of Alzheimer’s disease
Li “Joyce” Ouyang, joyceoyl@ust.hk , Abstract PSTR198.11
###
The Society for Neuroscience (SfN) is an organization of nearly 35,000 basic scientists and clinicians who study the brain and the nervous system.